Chinese Peptide Pharma: Mazdutide, Efsubaglutide, and the Asia Pipeline
The global peptide therapeutics landscape has been dominated by Western pharmaceutical giants for decades, with Novo Nordisk and Eli Lilly commanding headlines — and market share — with semaglutide and tirzepatide. But a seismic shift is underway. Chinese biotech companies are advancing a robust pipeline of incretin-based peptides that are not only competitive with Western counterparts but, in some cases, demonstrating differentiated mechanisms and impressive clinical data. The implications for global obesity and diabetes research are significant.
The Rise of Chinese GLP-1 Innovation
China's obesity epidemic has accelerated dramatically. According to a 2024 Lancet analysis01548-4), China now has the world's largest absolute number of people living with obesity, surpassing 180 million adults. This public health crisis has created enormous demand for effective pharmacotherapies and, with it, a wave of domestic investment in incretin biology.
Chinese regulatory bodies, particularly the National Medical Products Administration (NMPA), have streamlined approval pathways for innovative biologics, and the results are showing. At least a dozen GLP-1 receptor agonists and multi-agonist peptides from Chinese companies are now in clinical development, with several approaching or achieving regulatory approval.
Mazdutide: Innovent's Dual-Agonist Contender
Mazdutide (IBI362), developed by Innovent Biologics in partnership with Eli Lilly, is arguably the most advanced Chinese-origin peptide in the obesity and diabetes space. It is a once-weekly GLP-1/glucagon receptor dual agonist — a mechanism that differentiates it from pure GLP-1 agonists like semaglutide by engaging the glucagon receptor to increase energy expenditure and hepatic lipid oxidation alongside the appetite-suppressing effects of GLP-1 signaling.
In the GLORY-1 pivotal trial, mazdutide demonstrated remarkable efficacy in Chinese adults with obesity. Published results showed that participants receiving the 9 mg dose achieved a mean body weight reduction of 17.4% over 48 weeks, compared to 1.2% with placebo. These figures rival or exceed the weight loss seen with semaglutide 2.4 mg in the STEP trials.
The GLORY-2 trial extended mazdutide's evidence base into type 2 diabetes. Data presented at ADA 202401449-1) showed that the 9 mg dose achieved HbA1c reductions of approximately 1.5 percentage points alongside substantial weight loss of around 11.3% — a dual benefit that underscores the therapeutic potential of glucagon receptor co-agonism.
Mazdutide received its first approval from the NMPA in late 2024 for chronic weight management, making it the first GLP-1/glucagon dual agonist approved anywhere in the world. Innovent has also initiated global expansion plans, with trials registered to evaluate mazdutide in broader international populations.
The safety profile observed in trials has been broadly consistent with the GLP-1 agonist class — predominantly gastrointestinal adverse events including nausea, vomiting, and diarrhea. However, the glucagon component raises theoretical concerns about hepatic glucose output that warrant continued monitoring, particularly in patients with impaired glycemic control.
Efsubaglutide: An Fc-Fusion Approach
Efsubaglutide (LY3305677), originally discovered by Eli Lilly but licensed and co-developed with Chinese partners, represents another architectural approach to GLP-1 receptor agonism. It is a GLP-1-Fc fusion protein designed to achieve extended pharmacokinetics, potentially enabling less frequent dosing while maintaining sustained receptor engagement.
Early-phase clinical data from Chinese populations have shown promising glycemic control. Phase 2 results indicated significant HbA1c reductions and weight loss in patients with type 2 diabetes, though head-to-head comparisons with established agents remain limited.
The Fc-fusion platform is particularly interesting from a pharmacological perspective because it leverages FcRn-mediated recycling to extend half-life without requiring acylation-based albumin binding — the strategy employed by semaglutide. Whether this translates to clinically meaningful differences in efficacy, tolerability, or immunogenicity is an active area of research.
Beyond the Frontrunners: China's Broader Peptide Pipeline
Mazdutide and efsubaglutide represent only the tip of the iceberg. Several other Chinese companies are advancing differentiated incretin peptides:
This proliferation of candidates is not mere duplication. Many of these programs explore genuinely distinct pharmacology — oral formulations, novel multi-agonist combinations, and alternative delivery technologies including long-acting microsphere injections.
Structural and Mechanistic Differentiation
Understanding why these peptides differ requires appreciating the structural biology. Pure GLP-1 agonists like semaglutide act primarily on pancreatic beta cells and central appetite circuits. Dual GLP-1/glucagon agonists like mazdutide add a catabolic component: glucagon receptor activation in the liver promotes glycogenolysis, lipid oxidation, and thermogenesis, potentially driving greater fat-specific weight loss.
Triple agonists (GLP-1/GIP/glucagon) layer on GIP receptor activation, which appears to enhance insulin sensitivity and may amplify central appetite suppression through mechanisms that remain incompletely characterized. Coskun et al., 2022 provided foundational preclinical evidence for the synergistic effects of tri-agonism, demonstrating superior weight loss and metabolic improvements compared to mono- or dual-agonist approaches in animal models.
The Chinese pipeline is heavily invested across all three tiers of this agonist spectrum, positioning Chinese biotech to compete — or collaborate — with Western companies regardless of which mechanistic approach proves optimal.
Regulatory and Market Implications
The NMPA's willingness to approve mazdutide based on China-specific pivotal data sends an important signal. It suggests that Chinese regulators are prepared to move quickly on metabolic disease therapies, potentially creating a pathway for Chinese-developed peptides to reach patients faster domestically than through FDA or EMA processes.
For global research, this raises important questions about data generalizability. Pharmacogenomic differences in GLP-1 receptor signaling, body composition norms, and metabolic disease phenotypes between East Asian and Western populations mean that clinical results may not translate directly. Kim et al., 2023 highlighted that East Asian patients often develop type 2 diabetes at lower BMI thresholds, potentially altering the risk-benefit calculus for potent weight-loss agents.
International bridging studies will be critical. Several Chinese companies, including Innovent, have recognized this and are investing in global multi-regional clinical trials designed to support regulatory submissions in the US, EU, and other markets.
Competitive Landscape and Pricing Dynamics
Perhaps the most significant long-term impact of the Chinese peptide pipeline is on pricing and access. Current GLP-1 therapies from Novo Nordisk and Lilly carry substantial costs — often exceeding $1,000/month in the US without insurance. Chinese manufacturers have historically competed aggressively on price, and the entry of multiple domestic GLP-1 products into the Chinese market is expected to drive costs down significantly.
This pricing dynamic could have global ripple effects, particularly as Chinese companies pursue international approvals and as biosimilar versions of first-generation GLP-1 agonists approach patent expiration.